ALGORITHM FOR TREATMENT OF NVP

(HELP < 20)

- 1. B6/Pyridoxine with or without doxylamine: (Select ONE)
 - Pyridoxine 10–25 mg PO (with or without Doxylamine 12.5 mg PO), 3 or 4 times per day.
 - Pyridoxine + Doxylamine 10 mg, two tablets PO at bedtime, add one tablet in AM & afternoon prn.
 - Pyridoxine + Doxylamine 20 mg, one tablet PO at bedtime, add AM tablet prn.
- 2. Thiamin/Vitamin B1 10-100 mg PO 1-3 times per day. (250 mg daily minimum after 20 weeks)
- 3. Continue prenatal vitamin with iron and thiamin until not tolerated \rightarrow Switch to methylated folic acid.
- 4. Add gastric/esophageal protection. (See shaded box below.)



DEHYDRATION?



(HELP >32)

♦ (HELP <32)

Add up to 1 from each class:

- 1. Antihistamine (discontinue doxylamine before adding)
 - Dimenhydrinate 25-50 mg q 4-6 hours PO or PR (limit to 200 mg per day if taking doxylamine)
 - Diphenhydramine 25–50 mg PO q 4–6 hours
 - Meclizine 25 mg PO q 6 hours
- 2. Dopamine Antagonist
 - Metoclopramide 5-10 mg q 6-8 hours PO
 - Promethazine 12.5-25 mg q 4-6 hours PO or PR
 - Prochlorperazine 5-10 mg q 6-8 hours PO or 25 mg twice daily PR
- 1. Daily bowel regimen
 - Stool softener 1-2x/day + Laxative prn (1-3x/week)
 - Add Triple Mg prn
- 2. Ondansetron 4-8 mg q 6-8 hours PO or ODT, or ODT given vaginally **OR**
- 3. Granisetron 1 mg q 12 hours PO or 3 mg TD q 24 hours NOTE: Replace electrolytes & monitor EKG if cardiac risk.

Consider NUTRITION (see below) and one of the following:

- 1. Mirtazapine 15 mg q 8 hours PO or ODT (Dose not established for HG. Discontinue other serotonin antagonists.)
- 2. Methylprednisolone (if 10+ weeks) 16 mg q 8 hours PO or IV for 3 days. Taper over 2 weeks to lowest effective dose. Avoid duration exceeding 6 weeks.
- 3. Prochlorperazine 5-10 mg PO q 6-8 hours
- 4. Chlorpromazine 25–50 mg IV or 10–25 mg PO q 4-6 hours

GERD or gastric/esophageal protection:

- Calcium Antacid (avoid Bismuth or Bicarbonate)
 AND/OR
- 2. H2 antagonist BID: famotidine 20-40 mg OR
- 3. PPI q 24 hours
 - esomeprazole 30-40 mg PO or IV
 - lansoprazole 15-30 mg PO
 - pantoprazole 40 mg PO or IV

Select IV Fluids:

- 1. Banana Bag + Vit B6 + Vit B1
- 2. NS or Lactated Ringers + 1 ampule MVI + Vit B6 + Vit B1
- 3. D5NS or D5LR + 1 ampule MVI + Vit B6 + Vit B1
 - Add prn: KCl, Na, Vit K, Vit D, Zn, Se, Fe, Mg & Ca.
 - Always give 200 mg B1 with glucose to prevent WE.
 - Correct electrolytes slowly to prevent CPM.
 - Restrict PO intake for 24-48 hours for gut rest.
 - Consider midline or central line for frequent IVs.



If not responding to or tolerating PO meds, change to:

1. Thiamin 100-500 mg IV 3 times daily

AND ONE OF THE FOLLOWING

- 2. Dimenhydrinate 50 mg (in 50 mL saline, over 20 min) q 4–6 hours IV
- 3. Ondansetron**:
 - IV: 8 mg over 15 minutes q 12 hours or 4 mg q 6 hours IV or continuous infusion
 - SubQ continuous infusion: 8 mg starting dose, then 12-40 mg/day; wean slowly to PO.
- 4. Granisetron** 1mg q 12 hours IV
- 5. Metoclopramide:
 - IV: 5–10 mg q 8 hours
 - SubQ continuous infusion: 5-10 mg starting dose, then 20-40 mg/day; wean slowly to PO.
 - ** Daily Bowel Regimen required (see adjacent box)



NUTRITION - If weight loss ≥10% and/or persistent HG,

consult with GI & Nutrition & IV Therapy:

- 1. Enteral therapy: gradual infusion with or without additional parenteral/enteral fluids (Jejunal placement preferred)
- 2. Intravenous fluids and/or parenteral nutrition
 - Consider midline or central line.
 - Continue until gaining weight on PO intake.
 - Prevent Refeeding Syndrome: Slowly restart nutrition & monitor weight, phosphorus & electrolytes.

Disclaimer: This is not medical advice. Do not make any changes to your diet or lifestyle without consultation from your medical provider.

NOTES:

- 1. If symptoms persist, follow the arrows to the next level of care.
- 2. Most of these medications can cause QT prolongation, consider EKG or cardiac monitoring for high risk patients, high doses, multiple medications, or electrolyte abnormalities.
- 3. IM not recommended due to muscle loss and pain sensitivity.
- 4. Avoid using multiple dopamine antagonists simultaneously.
- 5. CPM = Central Pontine Myelinolysis; WE = Wernicke's encephalopathy
- 5. HELP = HyperEmesis Level Prediction Score, www.hyperemesis.org/tools



hyperemesis.org | HelpHER.org Email: info@hyperemesis.org

Algorithm Reviewed by HER Foundation Clinical Advisors & Board Members:

- 1. Aimee Brecht-Doscher, MD (Ventura County Healthcare)
- 2. Kimber MacGibbon, RN (HER Foundation)
- 3. Arielle Mitton, MD (University of Southern California, LA)
- 4. Patrick Mullin, MD (University of Southern California)
- 5. Linda Newgent, RN
- 6. Danielle Plummer, PharmD

SELECTED REFERENCES:

- 1. The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician: Nausea and Vomiting of Pregnancy. Obstet Gynecol. 2018;133(1):e15-e30.
- 2. Reichmann JP, Kirkbride MS. Reviewing the Evidence for Using Continuous Subcutaneous Metoclopramide and Ondansetron To Treat Nausea & Vomiting During Pregnancy A review of the available research identifies payment for services in the absence of high-quality scientific evidence and p. 2012;(May):44-47.
- 3. Klauser CK, Fox NS, Istwan N, et al. Treatment of severe nausea and vomiting of pregnancy with subcutaneous medications. Am J Perinatol. 2011;28(9):715-721. doi:10.1055/s-0031-1280594.
- 4. Lombardi DG, Istwan NB, Rhea DJ, et al. Measuring outpatient outcomes of emesis and nausea management in pregnant women. Manag Care. 2004;13(11):48-52.
- 5. Caritis S, Zhao Y, Chen HJ, et al. Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2016;215(1):93.e1-93.e4. doi:10.1016/j.ajog.2016.01.163.
- 6. Abramowitz A, Miller ES, Wisner KL. Treatment options for hyperemesis gravidarum. Arch Womens Ment Health. 2017;20(3):363-372. doi:10.1007/s00737-016-0707-4.
- 7. London V, Grube S, Sherer DM, et al. Hyperemesis gravidarum: A review of recent literature. Pharmacology. 2017;100(3-4):161-171. doi:10.1159/000477853.

DISLAIMER:

You understand and acknowledge that all users of this treatment algorithm are responsible for their own medical care, treatment, and oversight. All of the content provided is for informational purposes only and does NOT constitute medical advice, and is not intended as a substitute for independent professional medical judgment, advice, diagnosis, or treatment. You agree to hold HER Foundation and its representatives for any and all situations that arise from use of this information.

You understand and acknowledge that you should always seek the advice of your physician or other qualified health provider with any questions or concerns you may have regarding your health. You also understand and acknowledge that you should never disregard or delay seeking medical advice relating to treatment or standard of care because of information contained herein.